Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07283796 | A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 1 | 110 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07294625 | A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 19, 2025 |
| clinicaltrials |
| NCT05192122 | Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD(HEME-20) | recruiting | Phase 1 | 50 | University of Illinois at ChicagoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06736613 | A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma | recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07062627 | Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma | recruiting | Phase 2 | 12 | Hyungwoo ChoOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07189065 | A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 150 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07283822 | Amping up With PemJAK | recruiting | Phase 2 | 53 | Seda S. ToluOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07284927 | Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies | recruiting | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07285590 | Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma(IMCL-2023) | recruiting | Phase 2 | 50 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 2 | Dec 16, 2025 | clinicaltrials |
| NCT04268199 | A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment(EASE) | recruiting | Phase 2 | 100 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07052695 | Mosunetuzumab for CLL MRD Clearance | recruiting | Phase 1 / Phase 2 | 40 | Inhye AhnOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07280494 | To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT(S101MRD) | recruiting | Phase 1 | 18 | Peking University People's HospitalOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT06518551 | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | recruiting | Phase 1 / Phase 2 | 49 | Omar Nadeem, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07179679 | A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors | recruiting | Phase 1 | 42 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05602363 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | recruiting | Phase 1 | 120 | Carna Biosciences, Inc.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | recruiting | Phase 4 | 15 | University Health Network, TorontoOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02863692 | Registry of the German CLL Study Group(CLL-Registry) | recruiting | — | 8,000 | German CLL Study GroupOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05556928 | Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry(CARE-Heme) | recruiting | — | 5,000 | University of Alabama at BirminghamOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06156774 | SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project | recruiting | — | 130 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06803693 | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | recruiting | Phase 2 | 152 | Ruijin HospitalOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07270679 | Genetic Markers of Susceptibility to Chemotherapy-induced Ovarian Damage in Cancer Patients Undergoing Ovarian Biopsy for Cryopreservation. | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04925609 | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors(Briga-PED) | recruiting | Phase 1 / Phase 2 | 65 | Princess Maxima Center for Pediatric OncologyOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05168930 | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | recruiting | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06421948 | Linperlisib Combined With Chidamide in Patients With PTCL | recruiting | Phase 1 / Phase 2 | 134 | Yanyan LiuOTHER_GOV | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06986174 | A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia | recruiting | Phase 2 | 30 | Shayna Sarosiek, MDOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04871607 | Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma | recruiting | Phase 2 | 33 | City of Hope Medical CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06390956 | Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) | recruiting | Phase 2 | 23 | University of UtahOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06520163 | Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma | recruiting | Phase 3 | 99 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06237803 | European Myeloma Network (EMN) Sample Project(EMN36) | recruiting | — | 6,000 | European Myeloma Network B.V.NETWORK | 10 | Dec 3, 2025 | clinicaltrials |
| NCT06485076 | Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma(EPC-MM+L) | recruiting | N/A | 144 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06645678 | Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma(MELT-MM) | recruiting | Phase 1 / Phase 2 | 75 | YOUNGIL KOHOTHER | 2 | Dec 3, 2025 | clinicaltrials |
| NCT06920251 | Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy(OPTIMUS-EL) | recruiting | Phase 2 | 40 | Seoul National University HospitalOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06947083 | Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | recruiting | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06588868 | Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma(FIL_CTCL) | recruiting | — | 400 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07162012 | Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma(Anti-EBV TCR-T) | recruiting | Early Phase 1 | 24 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07257510 | Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma | recruiting | N/A | 34 | Peking University Third HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT00898235 | Collection of Samples and Clinical Data From Patients With Amyloid Diseases | recruiting | — | 10,000 | Boston Medical CenterOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05312255 | Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma | recruiting | N/A | 175 | Roswell Park Cancer InstituteOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07248176 | Universal CAR-T Cell Therapy for MM | recruiting | N/A | 6 | Bioray LaboratoriesINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07188090 | Mozobil for Autologous Hematopoietic Stem Cell Transplantation(HSCT) | recruiting | Phase 2 | 100 | Thomas Jefferson UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07254754 | Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma(LATE-R-GEL-23) | recruiting | Phase 2 | 45 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT04484012 | Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06508775 | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies(LONGSAFE) | recruiting | N/A | 40 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06984146 | Nivo40-AVD for Advanced Classic Hodgkin Lymphoma | recruiting | Phase 2 | 54 | National Medical Research Radiological Centre of the Ministry of Health of RussiaOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07003555 | Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07003568 | Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07084662 | Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma | recruiting | Phase 2 / Phase 3 | 80 | Sun Yat-sen UniversityOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05741359 | The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma | recruiting | Phase 1 | 18 | Bioray LaboratoriesINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06958705 | Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy | recruiting | Phase 2 | 79 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07139509 | Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma(UCAR-T_MM-XA) | recruiting | Phase 1 | 18 | Xi'an No.3 HospitalOTHER_GOV | 1 | Nov 25, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Dec 19, 2025source: clinicaltrials